|
시장보고서
상품코드
2077214
판코니 빈혈 치료제 시장 : 치료법별, 연령층별, 병기별, 지역별Fanconi Anemia Drug Market, By Treatment Type, By Age Group, By Disease Stage, By Geography |
||||||
가격
※ 부가세 별도
한글목차
영문목차
※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.
판코니 빈혈 치료제 시장은 2026년에 6억 6,770만 달러 규모에 달할 것으로 추정되며, 2033년까지 9억 5,850만 달러에 달할 것으로 전망됩니다. 2026년부터 2033년까지 CAGR 5.3%로 성장할 것으로 예측됩니다.
| 보고서 범위 | 보고서 상세 | ||
|---|---|---|---|
| 기준 연도: | 2025년 | 2026년 시장 규모: | 6억 6,770만 달러 |
| 과거 데이터 기간: | 2020-2024년 | 예측 기간: | 2026-2033년 |
| 2026년부터 2033년까지 예측 기간 CAGR: | 5.30% | 2033년 시장 규모 예측: | 9억 5,850만 달러 |
전 세계 판코니 빈혈 치료제 시장에는 조혈 성장 인자, 유전자 치료, 줄기세포 이식 및 이와 유사한 치료법 범주에 속하는 제품들이 포함됩니다. 이는 소아 환자와 성인 환자 모두에게 적용되며, 질병의 초기 단계 및 진행 단계에 있는 환자에게 사용되고 있습니다. 조직이 성과, 효율성, 비용 대비 효과를 점점 더 중시함에 따라, 이러한 부문에서의 채용은 꾸준히 확대되고 있습니다.
시장 역학:
초기 및 진행 단계 질환에 대한 수요 증가, 효율성과 신뢰성 향상의 필요성, 그리고 지속적인 제품 혁신이 전 세계 판코니 빈혈 치료제 시장의 성장을 견인할 것으로 예상되는 주요 요인입니다. 소아 및 성인 환자에 대한 적용 범위가 확대되면서 이러한 추세가 더욱 가속화되고 있습니다.
예를 들어, 시장에 진출한 각 기업은 소아 및 성인 환자를 위한 사용 사례에 맞춰 설계된 첨단 솔루션을 도입하고 있습니다. 또한, 지속적인 기술 발전과 전략적 투자를 통해 예측 기간 동안 시장에 진출한 기업들에게 새로운 성장 기회가 창출될 것으로 전망됩니다.
본 조사의 주요 특징:
- 본 조사에서는 다양한 부문의 잠재적 수익 기회를 파악하고, 이 시장에서 매력적인 투자 제안 매트릭스에 대해 설명하고 있습니다.
- 또한, 본 조사에서는 시장 촉진요인, 억제요인, 기회, 신제품 출시 및 승인, 시장 동향, 지역별 전망, 그리고 주요 기업들이 채택하는 경쟁 전략에 관한 중요한 인사이트를 제공합니다.
- 본 조사에서는 기업 개요, 제품 포트폴리오, 주요 하이라이트, 재무 실적, 전략 등의 지표를 바탕으로 전 세계 판코니 빈혈 치료제 시장의 주요 기업 개요을 소개하고 있습니다.
- 본 보고서를 통해 얻은 인사이트를 바탕으로, 기업의 마케팅 담당자 및 경영진은 향후 제품 출시, 제품 업그레이드, 시장 확대 및 마케팅 전략에 대해 정보에 입각한 의사결정을 내릴 수 있게 됩니다.
- 본 '세계 판코니 빈혈 치료제 시장' 보고서는 투자자, 공급업체, 제품 제조업체, 유통업체, 신규 진입 기업, 금융 애널리스트 등 이 업계의 다양한 이해관계자를 대상으로 합니다.
- 이해관계자 여러분은 전 세계 판코니 빈혈 치료제 시장 분석에 활용된 다양한 전략 매트릭스를 활용함으로써 의사결정을 원활하게 진행할 수 있을 것입니다.
목차
제1장 조사 목적과 가정
제2장 시장 전망
제3장 시장 역학·규제·동향 분석
제4장 세계의 판코니 빈혈 치료제
제5장 세계의 판코니 빈혈 치료제 시장 : 치료 유형별, 2021-2033년
제6장 세계의 판코니 빈혈 치료제 시장 : 연령층별, 2021-2033년
제7장 세계의 판코니 빈혈 치료제 시장 : 질환 스테이지별, 2021-2033년
제8장 세계의 판코니 빈혈 치료제 시장 : 지역별, 2021-2033년
제9장 경쟁 구도
제10장 섹션
KSM 26.07.07Fanconi Anemia Drug Market is estimated to be valued at USD 667.7 Mn in 2026 and is expected to reach USD 958.5 Mn by 2033, growing at a compound annual growth rate (CAGR) of 5.3% from 2026 to 2033.
| Report Coverage | Report Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 667.7 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 5.30% | 2033 Value Projection: | USD 958.5 Mn |
The global fanconi anemia drug market includes offerings that span Hematopoietic Growth Factors, Gene Therapy, and Stem Cell Transplantation, and similar treatment type categories. These are applied across Pediatric Patients and Adult Patients and adopted by Early-stage Disease and Advanced-stage Disease. As organizations increasingly prioritize performance, efficiency, and cost-effectiveness, adoption across these segments continues to grow steadily.
Market Dynamics:
Increasing demand from Early-stage Disease and Advanced-stage Disease, the need for improved efficiency and reliability, and ongoing product innovation are major factors expected to drive growth of the global fanconi anemia drug market. Broader adoption across Pediatric Patients and Adult Patients is reinforcing this momentum.
For instance, market players are introducing advanced solutions designed for Pediatric Patients and Adult Patients use cases. Moreover, continued technological advancement and strategic investment are expected to create new growth opportunities for market players over the forecast period.
Key features of the study:
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market.
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players.
- It profiles key players in the global fanconi anemia drug market based on the following parameters such as company highlights, products portfolio, key highlights, financial performance, and strategies.
- Key companies covered as a part of this study include Foresee Pharmaceuticals Co, Ltd., Rocket Pharmaceuticals Inc., Amgen, Novartis AG, Gilead Sciences, Inc. (Kite Pharma, Inc.), Celgene Corporation (Juno Therapeutics), Spark Therapeutics, UniQure N.V, Bluebird Bio, Inc., PTC Therapeutics, Orchard Therapeutics Limited, GlaxoSmithKline Plc., Aurora Biopharma, Inc., Pfizer, and Inc. and Autolus Therapeutics, among others.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global fanconi anemia drug market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global fanconi anemia drug market.
Detailed Segmentation:
- Global Fanconi Anemia Drug Market, By Treatment Type (Revenue, USD Bn, 2021 - 2033)
- Hematopoietic Growth Factors
- Gene Therapy
- Stem Cell Transplantation
- Other Therapies
- Global Fanconi Anemia Drug Market, By Age Group (Revenue, USD Bn, 2021 - 2033)
- Pediatric Patients and Adult Patients
- Global Fanconi Anemia Drug Market, By Disease Stage (Revenue, USD Bn, 2021 - 2033)
- Early-stage Disease and Advanced-stage Disease
- Regional Insights (Revenue, USD Bn, 2021 - 2033)
- North America
- U.S.
- Canada
- Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- GCC Countries
- Israel
- Rest of Middle East
- Africa
- South Africa
- North Africa
- Central Africa
- Company Profiles:
- Foresee Pharmaceuticals Co, Ltd.*
- Company Overview
- Product Portfolio
- Financial Performance
- Recent Developments/Updates
- Strategies
- Rocket Pharmaceuticals Inc.
- Amgen
- Novartis AG
- Gilead Sciences
- Inc. (Kite Pharma, Inc.)
- Celgene Corporation (Juno Therapeutics)
- Spark Therapeutics
- UniQure N.V
- Bluebird Bio, Inc.
- PTC Therapeutics
- Orchard Therapeutics Limited
- GlaxoSmithKline Plc.
- Aurora Biopharma, Inc.
- Pfizer
- Inc. and Autolus Therapeutics
"*" marked represents similar segmentation in other categories in the respective section.
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Fanconi Anemia Drug, By Treatment Type
- Market Fanconi Anemia Drug, By Age Group
- Market Fanconi Anemia Drug, By Disease Stage
- Market Fanconi Anemia Drug, By Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Drivers
- Continuous advancements in scientific research and understanding of the molecular mechanisms
- Substantial unmet medical need
- Restraints
- Lack of recognized therapies
- Opportunities
- Development of Disease-Modifying Therapies
- Drivers
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product Launches/Approvals
- PEST Analysis
- PORTER€(TM)s Analysis
- Merger and Acquisition Scenario
4. Global Fanconi Anemia Drug
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Fanconi Anemia Drug Market, By Treatment Type, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Hematopoietic Growth Factors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Gene Therapy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Stem Cell Transplantation
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Other Therapies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
6. Global Fanconi Anemia Drug Market, By Age Group, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Pediatric Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Adult Patients
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
7. Global Fanconi Anemia Drug Market, By Disease Stage, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022€"2033
- Segment Trends
- Early-stage Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
- Advanced-stage Disease
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Mn)
8. Global Fanconi Anemia Drug Market, By Region, 2021 - 2033, (US$ Mn)
- Introduction
- Market Share Analysis, By Region, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, For Region, 2022 €"2033
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- U.S.
- Canada
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- Brazil
- Argentina
- Mexico
- Rest of Latin America
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- GCC
- Israel
- Rest of Middle East
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Treatment Type, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Age Group, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Disease Stage, 2021 - 2033, (US$ Mn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033,(US$ Mn)
- South Africa
- North Africa
- Central Africa
9. Competitive Landscape
- Foresee Pharmaceuticals Co., Ltd.
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Rocket Pharmaceuticals Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Amgen
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Novartis AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Gilead Sciences, Inc. (Kite Pharma, Inc.)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Celgene Corporation (Juno Therapeutics)
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Spark Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- UniQure N.V
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bluebird Bio, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- PTC Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Orchard Therapeutics Limited
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline Plc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Aurora Biopharma, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Pfizer, Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Autolus Therapeutics
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
10. Section
- Research Methodology
- About us
